Feature

Not all lung cancer patients receive treatment


 

In the United States, just over 15% of patients with lung cancer receive no treatment, according to the American Lung Association.

Percentage of people with lung cancer who received no treatment

“This can happen for multiple reasons, such as the tumor having spread too far, poor health, or refusal of treatment,” the ALA said in its 2019 State of Lung Cancer report.

On the state level, the disparities were considerable. Arizona had the highest rate of nontreatment at 30.4%, followed by the neighboring states of New Mexico (24.2%) and California (24.0%). The lowest rate in the country, 8.0%, came from North Dakota, with Missouri next at 9.4% and Maine third at 9.6%, based on data from the North American Association of Central Cancer Registries’ December 2018 data submission, which covered the years from 2012 to 2016.

Although some cases of lung cancer may be unavoidable, “no one should go untreated because of lack of provider or patient knowledge, stigma associated with lung cancer, fatalism after diagnosis, or cost of treatment. Dismantling these and other barriers is important to reducing the percent of untreated patients,” the ALA said.

Recommended Reading

More liberal criteria could greatly expand clinical trial participation
Journal of Clinical Outcomes Management
Pembrolizumab improves 5-year OS in advanced NSCLC
Journal of Clinical Outcomes Management
FDA approves pembrolizumab for advanced SCLC
Journal of Clinical Outcomes Management
COPD adds complexity to shared decision making for LDCT lung cancer screening
Journal of Clinical Outcomes Management
Many institutions exceed recommended radiation doses during lung cancer screening
Journal of Clinical Outcomes Management
PACIFIC: Patterns of lung cancer progression suggest role for local ablative therapy
Journal of Clinical Outcomes Management
OS benefit with pembrolizumab endures long-term in advanced NSCLC
Journal of Clinical Outcomes Management
Cardiotoxicity after checkpoint inhibitor treatment seen early, linked to elevated biomarkers
Journal of Clinical Outcomes Management
Immunotherapy duo extends survival in first line for advanced NSCLC
Journal of Clinical Outcomes Management
Lung cancer screening, early diagnosis still lower among blacks, Hispanics
Journal of Clinical Outcomes Management